Cyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.26, for a total transaction of $61,300.00. Following the sale, the director now directly owns 756,283 shares of the company’s stock, valued at approximately $9,272,029.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Cyrus Harmon also recently made the following trade(s):

• On Friday, June 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.77, for a total transaction of $215,400.00.
• On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.93, for a total transaction of $54,650.00.
• On Friday, May 31st, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.92, for a total transaction of $54,600.00.
• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $142,650.00.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA traded down $0.20 during trading on Friday, reaching $12.30. The company’s stock had a trading volume of 861,008 shares, compared to its average volume of 871,233. The firm has a market cap of $687.94 million, a price-to-earnings ratio of -6.09 and a beta of 2.06. Olema Pharmaceuticals, Inc. has a twelve month low of $7.78 and a twelve month high of $17.79. The business’s fifty day moving average price is $11.03 and its 200-day moving average price is $11.91.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.03). As a group, sell-side analysts forecast that Olema Pharmaceuticals, Inc. will post -2.3 EPS for the current fiscal year.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its holdings in Olema Pharmaceuticals by 3.4% during the first quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock worth $393,000 after buying an additional 1,132 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Olema Pharmaceuticals by 74.5% in the first quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock valued at $13,817,000 after buying an additional 521,562 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Olema Pharmaceuticals by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after buying an additional 1,486 shares during the last quarter. EntryPoint Capital LLC raised its position in shares of Olema Pharmaceuticals by 949.9% in the first quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock valued at $164,000 after buying an additional 13,146 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in Olema Pharmaceuticals during the first quarter worth approximately $161,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on OLMA. The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Tuesday, June 4th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $22.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.